Dr. Marc Gurwith

Verndari, Inc., USA
Atom Bioscience,USA

Chief Medical Officer

Email: [email protected]

Qualifications

1991 J.D., Temple University School of Law, Law

1965 M.D., Harvard Medical School, Medicine

1961 B.A., Yale University, Philosophy

Publications (selected)

1. Link, E. K., Tscherne, A., Sutter, G., et al. (2025). A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector. Vaccine, 43(1), Article 126521.
2. Spurgers, K., Wynn, M., Charles, L., et al. (2025). A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever. Vaccine, 58, Article 127137.
3. Gurwith, M., Wu, R. J., Schwertschlag, U., et al. (2025). Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Oral Doses of ABP-671 in Healthy and Hyperuricemic Subjects. Drug Design Development and Therapy, 19, 10607-10620.
4. Pather, S., Charpentier, N., van den Ouweland, F., et al. (2024). A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine. Vaccine, 42(22), Article 126165.
5. Wilkinson, B., Patel, K. S., Smith, K., et al. (2023). A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses. Vaccine, 41(45), 6762-6773.
6. Estephan, L., Liu, L. T. C., Lien, C. E., et al. (2023). A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine. Vaccine, 41(15), 2615-2629.
7. Gurwith, M., Smith, D., Bird, P., et al. (2022). A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia. Arthritis & Rheumatology, 74(Suppl. 9), 3601-3603.
8. Folegatti, P. M., Jenkin, D., Morris, S., et al. (2022). Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 40(35), 5248-5262.
9. Hernandez, L. M., Sumathy, K., Sahastrabuddhe, S., et al. (2022). A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus. Vaccine, 40(35), 5263-5274.
10. Leav, B., Straus, W., White, P., et al. (2022). A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). Vaccine, 40(35), 5275-5293.
11. Eldridge, H. J., Egan, A. M., Matassov, D., et al. (2021). A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses. Vaccine, 39(38), 5436-5441.
12. Custers, J., Kim, D., Leyssen, M., et al. (2021). Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 39(22), 3081-3101.
13. Munoz, F. M., Cramer, J. P., Dekker, C. L., et al. (2021). Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 39(22), 3053-3066.
14. Black, S. B., Law, B., Chen, R. T., et al. (2021). The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine, 39(19), 2712-2718.
15. Matsuda, K., Migueles, S. A., Huang, J. H., et al. (2021). A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. Journal of Clinical Investigation, 131(5), Article e140794.
16. Condit, R. C., Kim, D., Robertson, J. S., et al. (2020). The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. Vaccine, 38(49), 7708-7715.
17. Gurwith, M., Condit, R. C., Excler, J. L., et al. (2020). Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. Vaccine, 38(49), 7702-7707.
18. Kochhar, S., Excler, J. L., Kim, D., et al. (2020). The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines. Vaccine, 38(39), 6184-6189.
19. Kochhar, S., Kim, D., Excler, J. L., et al. (2020). The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. Vaccine, 38(35), 5734-5739.
20. Kim, D., Robertson, J. S., Excler, J. L., et al. (2020). The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. Vaccine, 38(34), 5556-5561.

Profile Details

https://www.healthcentral.com/author/marc-gurwith
https://www.researchgate.net/profile/Marc-Gurwith

WOS ResearcherID: FBA-4106-2022